Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Tuesday, May 8, 2018

World’s First Stem Cell Therapy In Alzheimer’s Disease Is Approved

You'll need to discuss with your doctor since you will likely get this. Assuming your doctor even knows your chances of getting Alzheimers/dementia.

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.
3. A 20% chance in this research.   July 2013.


World’s First Stem Cell Therapy In Alzheimer’s Disease Is Approved


First stem cell treatment, approved in Japan recently, developed by a joint venture between a biotech company named Nature Cell and the Biostar Stem Cell Research Institute in South Korea. This treatment is to treat mild-to-moderate Alzheimer’s disease (AD) patients. AD is characterized by neuronal loss, cognitive dysfunction and loss of memory. They received approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) for the application of regenerative medicine in AD which allows them officially to begin stem cell treatment. Biostar will support Alzheimer’s patients from all over the world to restore their memory. According to the media, around 80 patients already booked for the treatment initially following approval.
Trinity Clinic Fukuoka, a partner hospital in Japan, started the first stem cell treatment to three Korean Alzheimer’s patients to measure the safety and effectiveness of adipose tissue -derived  mesenchymal  stem  cells  (ATMSCs).  The patients were administered with 200 million cells 10 times in every two weeks. The investigators administered autologous adipose tissue-derived mesenchymal stem cells intravenously. Moreover, the safety of intravenous infusion techniques has been established in multiple clinical trials in the United States also. Dr. Ra (CEO of RNL Bio) developed this technology to purify stem cells from fat tissue and grow them in culture. The research team led by Dr. Ra has demonstrated in many journals that stem cells isolated from patient’s own tissue can be used for therapeutic intervention in diseases. His research team showed previously the effectiveness of ATMSCs in animal model of AD.
ATMSC jpeg
Major sources of human mesenchymal stem cells (MSC) . The sources can be distinguished between adult tissues, preferably bone marrow (BM), peripheral blood (PB) and adipose tissue (AT) and neonatal birth-associated tissues including placenta (PL), umbilical cord (UC) and cord blood (CB).                                                   This figure is a typical representation about background biology about MSC. Image credit: Cell Commun Signal, 2011
In general, ATMSCs  are becoming increasingly popular for use in regenerative  cell therapy because minimally invasive techniques are used. ATMSCs are capable of passing the blood-brain barrier. They populate in the entire central nervous system by differentiating mainly in microglial cells. Previously, researchers found that these migrated stem cells can play a neuroprotective role in AD model.  They reported that these cells attenuate amyloid β-induced damage and inhibit neuronal cell death. Reduction of amyloid β disposition was also shown in earlier research.

No comments:

Post a Comment